DRUG QUANTITY MANAGEMENT POLICY – PER DAYS
POLICY: Inflammatory Conditions – Cosentyx Subcutaneous Drug Quantity
Management Policy – Per Days
• Cosentyx® (secukinumab subcutaneous injection – Novartis)
REVIEW DATE: 10/02/2024
INSTRUCTIONS FOR USE
THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA
COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE
DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE
CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS
ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP
SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN
DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR
EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE
POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE
COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY
DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE
REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY
APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE
SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL
DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE
DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES
ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS,
DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.
CIGNA NATIONAL FORMULARY COVERAGE:
OVERVIEW
Cosentyx, an interleukin (IL)-17A antagonist, is indicated in the following
conditions:1
• Plaque psoriasis, in patients ≥ 6 years of age with moderate to severe
disease who are candidates for systemic therapy or phototherapy.
• Psoriatic arthritis, in patients ≥ 2 years of age with active disease.
• Ankylosing spondylitis, in adults with active disease.
• Non-radiographic axial spondyloarthritis, in adults with active disease
and objective signs of inflammation.
• Enthesitis-related arthritis in patients ≥ 4 years of age with active
disease.
• Hidradenitis suppurativa, in adults with moderate to severe disease.
Dosing
Cosentyx is administered by subcutaneous (SC) injection.1
• Ankylosing Spondylitis: Administer with or without a loading dose.
o With a loading dose: 150 mg at Weeks 0, 1, 2, 3, and 4, then 150 mg once
every 4 weeks (Q4W) thereafter.
Page 1 of 5 - Cigna National Formulary Coverage - Policy:Inflammatory Conditions – Cosentyx Subcutaneous
Drug Quantity Management Policy – Per Days
o Without a loading dose: 150 mg Q4W.
o If the patient continues to have active ankylosing spondylitis, consider 300
mg Q4W.
• Plaque Psoriasis:
o Adults: 300 mg at Weeks 0, 1, 2, 3, and 4, followed by 300 mg Q4W. For
some patients, 150 mg Q4W may be acceptable.
o Pediatric patients ≥ 6 years of age: Dose is based on body weight and is
administered at Weeks 0, 1, 2, 3, and 4 followed by Q4W dosing. The dose
is 75 mg for patients weighing < 50 kg and is 150 mg for patients weighing
≥ 50 kg.
• Psoriatic Arthritis: Cosentyx may be administered with or without
methotrexate.
o Adults with coexistent moderate to severe plaque psoriasis: Use the dosing
and administration recommendations for plaque psoriasis.
o Other adults with psoriatic arthritis: Administer with or without a loading
dose.
▪ With a loading dose: 150 mg at Weeks 0, 1, 2, 3, and 4, then 150 mg
Q4W thereafter.
▪ Without a loading dose: 150 mg Q4W.
▪ If the patient continues to have active psoriatic arthritis, consider 300 mg
Q4W.
o Pediatric patients ≥ 2 years of age: Dose is based on body weight and is
administered at Weeks 0, 1, 2, 3, and 4 followed by Q4W dosing. The dose
is 75 mg for patients weighing ≥ 15 kg and < 50 kg and is 150 mg for
patients weighing ≥ 50 kg.
• Non-radiographic axial spondyloarthritis: Administer with or without a
loading dose.
o With a loading dose: 150 mg at Weeks 0, 1, 2, 3, and 4, then 150 mg Q4W
thereafter.
o Without a loading dose: 150 mg Q4W.
• Enthesitis-related arthritis: Dose is based on body weight and is
administered at Weeks 0, 1, 2, 3, and 4, followed by Q4W dosing. The dose is
75 mg for patients weighing ≥ 15 kg and < 50 kg and is 150 mg for patients
weighing ≥ 50 kg.
• Hidradenitis suppurativa: 300 mg at Weeks 0, 1, 2, 3, and 4, then 300 mg
Q4W thereafter.
o If the patient does not adequately respond, the dose may be increased to
300 mg Q2W.
Availability
Cosentyx is available in the following forms:
• 300 mg/2 mL single-dose UnoReady pen (cartons contain one pen).
• 300 mg/2 mL single-dose prefilled syringe (cartons contain one prefilled syringe)
• 150 mg/mL single-dose SensoReady pen (cartons contain either one or two
pens).
• 150 mg/mL single-dose prefilled syringe (cartons contain either one or two
prefilled syringes).
5 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions – Cosentyx Subcutaneous Drug
Quantity Management Policy – Per Days
• 75 mg/0.5 mL single-dose prefilled syringe (cartons contain one prefilled
syringe) [for pediatric patients who weigh < 50 kg].
Of note, Cosentyx is also available as a 125 mg/5 mL intravenous (IV) solution.
The IV solution is not targeted in this policy.
POLICY STATEMENT
This Drug Quantity Management program has been developed to promote the safe,
effective, and economic use of Cosentyx, and to manage potential premature dose
escalation. If the Drug Quantity Management rule is not met at the point of
service, coverage will be determined by the Criteria below. All approvals are
provided for 1 year in duration unless otherwise noted below.
Drug Quantity Limits
Product Strength and Form Retail Home Delivery
Maximum Maximum
Quantity Quantity
per 28 Days Per 84 Days
Cosentyx® 300 mg/2 mL UnoReady 2 mL 6 mL
(secukinumab pen (1 pen) (3 pens)
subcutaneous injection) 300 mg/2 mL prefilled 2 mL 6 mL
syringe (1 prefilled syringe) (3 prefilled
syringes)
150 mg/mL prefilled 2 mL 6 mL
syringe (2 prefilled (6 prefilled
syringes) syringes)
150 mg/mL SensoReady 2 mL 6 mL
pen (2 pens) (6 pens)
75 mg/0.5 mL prefilled 0.5 mL 1.5 mL
syringe (1 prefilled syringe) (3 prefilled
syringes)
Inflammatory Conditions – Cosentyx Subcutaneous Drug Quantity
Management Policy – Per Days product(s) is(are) covered as medically
necessary when the following criteria is(are) met. Any other exception is
considered not medically necessary.
CRITERIA
Cosentyx 300 mg prefilled syringes or UnoReady pens
1. If the patient is initiating treatment for plaque psoriasis or hidradenitis
suppurativa OR requires additional induction dosing for plaque psoriasis or
hidradenitis suppurativa, as verified by the absence of claims for Cosentyx in the
past 130 days, approve a one-time override for 10 mL (5 prefilled syringes or
pens) at retail or 14 mL (7 prefilled syringes or pens)at home delivery.
5 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions – Cosentyx Subcutaneous Drug
Quantity Management Policy – Per Days
2. If the patient requires a dose of 300 mg once every 2 weeks for hidradenitis
suppurativa, approve 4 mL (2 prefilled syringes or pens) per 28 days at retail or
12 mL (6 prefilled syringes or pens) per 84 days at home delivery.
Cosentyx 150 mg prefilled syringes or SensoReady pens
1. If the patient is initiating treatment for ankylosing spondylitis, non-radiographic
axial spondyloarthritis, psoriatic arthritis, or enthesitis-related arthritis OR
requires additional induction dosing for ankylosing spondylitis, non-radiographic
axial spondyloarthritis, psoriatic arthritis, or enthesitis-related arthritis as
verified by the absence of claims for Cosentyx in the past 130 days, approve a
one-time override for 5 mL (5 prefilled syringes or pens) at retail or 7 mL (7
prefilled syringes or pens) at home delivery.
2. If the patient is initiating treatment for plaque psoriasis or hidradenitis
suppurativa OR requires additional induction dosing for plaque psoriasis or
hidradenitis suppurativa, as verified by the absence of claims for Cosentyx in the
past 130 days, approve a one-time override for 10 mL (10 prefilled syringes or
pens) at retail or 12 mL (12 prefilled syringes or pens) at home delivery.
3. If the patient requires a dose of 300 mg once every 2 weeks for hidradenitis
suppurativa, approve 4 mL (4 prefilled syringes or pens) per 28 days at retail or
12 mL (12 prefilled syringes or pens) per 84 days at home delivery.
Cosentyx 75 mg prefilled syringes
1. If the patient is initiating treatment for plaque psoriasis, psoriatic arthritis, or
enthesitis-related arthritis OR requires additional induction dosing for plaque
psoriasis, psoriatic arthritis, or enthesitis-related arthritis, as verified by the
absence of claims for Cosentyx in the past 130 days, approve a one-time
override for 2.5 mL (5 prefilled syringes) at retail or 3 mL (6 prefilled syringes or
pens) at home delivery.
REFERENCES
1. Cosentyx® subcutaneous injection [prescribing information]. East Hanover, NJ: Novartis; August
2024.
History
Type of Summary of Changes Review
Revision Date
Early Annual Cosentyx 300 mg UnoReady pens: Added new quantity limit to 09/27/2023
Revision the policy of 1 pen per 28 days at retail or 3 pens per 84 days at
home delivery. Added new override criteria to approve a one-time
override for 5 pens at retail or 7 pens at home delivery if the patient
is initiating treatment or requires additional induction dosing for
plaque psoriasis.
Selected Name of policy updated to “Inflammatory Conditions – Cosentyx 11/15/2023
Revision Subcutaneous DQM Policy – Per Days”. Previously, policy was
named “Inflammatory Conditions – Cosentyx DQM Policy – Per
Days”.
5 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions – Cosentyx Subcutaneous Drug
Quantity Management Policy – Per Days
Cosentyx 300 mg UnoReady pens: New override criteria were
added to approve a one-time override for 5 pens at retail or 7 pens
at home delivery if the patient is initiating treatment for hidradenitis
suppurativa or requires additional induction dosing for hidradenitis
suppurativa. Additional criteria were added to approve 2 pens per
28 days at retail or 6 pens per 84 days at home delivery, if the
patient requires a dose of 300 mg once every 2 weeks for
hidradenitis suppurativa.
Cosentyx 150 mg prefilled syringes or SensoReady pens: New
override criteria were added to approve a one-time override for 10
prefilled syringes or pens at retail or 12 prefilled syringes or pens at
home delivery if the patient is initiating treatment for hidradenitis
suppurativa or requires additional induction dosing for hidradenitis
suppurativa. Additional criteria were added to approve 4 prefilled
syringes or pens per 28 days at retail or 12 prefilled syringes or pens
per 84 days at home delivery, if the patient requires a dose of 300
mg once every 2 weeks for hidradenitis suppurativa.
Annual Cosentyx 300 mg prefilled syringes: New quantity limits were 10/02/2024
Revision added to the policy of 2 mL (1 prefilled syringe) per 28 days at retail
or 6 mL (3 prefilled syringes) per 84 days at home delivery. New
override criteria were added to approve a one-time override for 10
mL (5 prefilled syringes) at retail or 14 mL (7 prefilled syringes) at
home delivery if the patient is initiating treatment for plaque
psoriasis or hidradenitis suppurativa or requires additional induction
dosing for plaque psoriasis or hidradenitis suppurativa. Additional
criteria were added to approve 4 mL (2 prefilled syringes) per 28
days at retail or 12 mL (6 prefilled syringes) per 84 days at home
delivery, if the patient requires a dose of 300 mg once every 2 weeks
for hidradenitis suppurativa.
"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are
provided exclusively by or through such operating subsidiaries, including Cigna Health and Life
Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc.,
Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. ©
2024 The Cigna Group.
5 Pages - Cigna National Formulary Coverage - Policy:Inflammatory Conditions – Cosentyx Subcutaneous Drug
Quantity Management Policy – Per Days